Literature DB >> 12186889

The antiviral response to gamma interferon.

Ana P Costa-Pereira1, Timothy M Williams, Birgit Strobl, Diane Watling, James Briscoe, Ian M Kerr.   

Abstract

A role for alpha/beta interferon (IFN-alpha/beta) in the IFN-gamma antiviral response has long been suggested. Accordingly, possible roles for autocrine or double-stranded-RNA (dsRNA)-induced IFN-alpha/beta in the IFN-gamma response were investigated. Use was made of wild-type and a variety of mutant human fibrosarcoma cell lines, including mutant U5A cells, which lack a functional IFN-alpha/beta receptor and hence an IFN-alpha/beta response. IFN-gamma did not induce detectable levels of IFN-alpha/beta in any of the cell lines, nor was the IFN-gamma response per se dependent on autocrine IFN-alpha/beta. On the other hand, a number of responses to dsRNA [poly(I). poly(C)] and encephalomyocarditis virus were greatly enhanced by IFN-gamma pretreatment (priming) of wild-type cells or of mutant cells lacking an IFN-alpha/beta response; these include the primary induction of dsRNA-inducible mRNAs, including IFN-beta mRNA, and, to a lesser extent, the dsRNA-mediated activation of the p38 mitogen-activated protein (MAP) kinase(s). IFN-gamma priming of mRNA induction by dsRNA is dependent on JAK1 and shows biphasic kinetics, with an initial rapid (<30-min) response being followed by a more substantial effect on overnight incubation. The IFN-gamma-primed dsRNA responses appear to be subject to modulation through the p38, phosphatidylinositol 3-kinase, and ERK1/ERK2 MAP kinase pathways. It can be concluded that despite efficient priming of IFN-beta production, the IFN-alpha/beta pathways play no significant role in the primary IFN-gamma antiviral response in these cell-virus systems. The observed IFN-gamma priming of dsRNA responses, on the other hand, will likely play a significant role in combating virus infection in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12186889      PMCID: PMC136459          DOI: 10.1128/jvi.76.18.9060-9068.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  Viral subversion of the immune system.

Authors:  D Tortorella; B E Gewurz; M H Furman; D J Schust; H L Ploegh
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  How cells respond to interferons.

Authors:  G R Stark; I M Kerr; B R Williams; R H Silverman; R D Schreiber
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

3.  Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains.

Authors:  A Takaoka; Y Mitani; H Suemori; M Sato; T Yokochi; S Noguchi; N Tanaka; T Taniguchi
Journal:  Science       Date:  2000-06-30       Impact factor: 47.728

4.  Activation of p38 mitogen-activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase R, and alternative pathways.

Authors:  M S Iordanov; J M Paranjape; A Zhou; J Wong; B R Williams; E F Meurs; R H Silverman; B E Magun
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

5.  Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways.

Authors:  A Zhou; J M Paranjape; S D Der; B R Williams; R H Silverman
Journal:  Virology       Date:  1999-06-05       Impact factor: 3.616

6.  A new pathway of translational regulation mediated by eukaryotic initiation factor 3.

Authors:  J Guo; D J Hui; W C Merrick; G C Sen
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

7.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.

Authors:  K C Goh; S J Haque; B R Williams
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

8.  NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice.

Authors:  E M Schwarz; C Badorff; T S Hiura; R Wessely; A Badorff; I M Verma; K U Knowlton
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins.

Authors:  M David; E Petricoin; C Benjamin; R Pine; M J Weber; A C Larner
Journal:  Science       Date:  1995-09-22       Impact factor: 47.728

10.  Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster.

Authors:  G Lutfalla; S J Holland; E Cinato; D Monneron; J Reboul; N C Rogers; J M Smith; G R Stark; K Gardiner; K E Mogensen
Journal:  EMBO J       Date:  1995-10-16       Impact factor: 11.598

View more
  14 in total

Review 1.  Lymphocytes and macrophages in adipose tissue in obesity: markers or makers of subclinical inflammation?

Authors:  Anna Cinkajzlová; Miloš Mráz; Martin Haluzík
Journal:  Protoplasma       Date:  2017-02-01       Impact factor: 3.356

2.  Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders.

Authors:  Gudrun Szalay; Martina Sauter; Joachim Hald; Andreas Weinzierl; Reinhard Kandolf; Karin Klingel
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

3.  TLR3 activation evokes IL-6 secretion, autocrine regulation of Stat3 signaling and TLR2 expression in human bronchial epithelial cells.

Authors:  Tamene Melkamu; Hirohito Kita; Scott M O'Grady
Journal:  J Cell Commun Signal       Date:  2012-12-13       Impact factor: 5.782

4.  A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells.

Authors:  Angel N Morrow; Hana Schmeisser; Takaya Tsuno; Kathryn C Zoon
Journal:  J Immunol       Date:  2010-12-22       Impact factor: 5.422

5.  Oligoadenylate synthetase/protein kinase R pathways and alphabeta TCR+ T cells are required for adenovirus vector: IFN-gamma inhibition of herpes simplex virus-1 in cornea.

Authors:  Bobbie Ann Austin; William P Halford; Bryan R G Williams; Daniel J J Carr
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

6.  Antiviral activity of salmonid gamma interferon against infectious pancreatic necrosis virus and salmonid alphavirus and its dependency on type I interferon.

Authors:  Baojian Sun; Ingrid Skjæveland; Tina Svingerud; Jun Zou; Jorunn Jørgensen; Børre Robertsen
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

7.  OAS and PKR are not required for the antiviral effect of Ad:IFN-gamma against acute HSV-1 in primary trigeminal ganglia cultures.

Authors:  Bobbie Ann Austin; William Halford; Robert H Silverman; Bryan R G Williams; Daniel J J Carr
Journal:  J Interferon Cytokine Res       Date:  2006-04       Impact factor: 2.607

8.  Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state.

Authors:  Kai A Kropp; Kevin A Robertson; Garwin Sing; Sara Rodriguez-Martin; Mathieu Blanc; Paul Lacaze; Muhamad F B Noor Hassim; Mizanur R Khondoker; Andreas Busche; Paul Dickinson; Thorsten Forster; Birgit Strobl; Mathias Mueller; Stipan Jonjic; Ana Angulo; Peter Ghazal
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

9.  STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1.

Authors:  Katarzyna Blaszczyk; Adam Olejnik; Hanna Nowicka; Lilla Ozgyin; Yi-Ling Chen; Stefan Chmielewski; Kaja Kostyrko; Joanna Wesoly; Balint Laszlo Balint; Chien-Kuo Lee; Hans A R Bluyssen
Journal:  Biochem J       Date:  2015-03-15       Impact factor: 3.857

10.  Efficacy of IFN-λ1 to protect human airway epithelial cells against human rhinovirus 1B infection.

Authors:  Fahad Gulraiz; Carla Bellinghausen; Mieke A Dentener; Niki L Reynaert; Giel R Gaajetaan; Erik V Beuken; Gernot G Rohde; Cathrien A Bruggeman; Frank R Stassen
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.